Over one million people suffer from Inflammatory bowel disease (IBD) in the US alone. Researchers today are working to improve quality of life for IBD patients with treatments that make the chronic, life-long condition more manageable. Clinical trials that accurately collect patient-reported outcomes and calculate symptom scores contribute to this effort.
Why Signant Health
Enhance Primary Endpoints
Gain Expert Guidance
Calculate Accurate Scores
Improve Patient Engagement
Simplify Participation
Digitalize the Entire Study
Enhance Primary Endpoints
Enhance Primary Endpoints
As part of our eCOA solution, the IBD Diary collects patient-reported outcomes through an easy-to-use, electronic format to encourage daily completion and improve data quality.
Gain Expert Guidance
Gain Expert Guidance
Signant’s scientific and clinical experts will help you navigate common study challenges such as identifying key data points and ensuring that complex scores are calculated correctly.
Calculate Accurate Scores
Calculate Accurate Scores
Signant’s eCOA solution can complete the required scoring calculations, eliminating the risk of manual errors and the need for another integrated system.
Improve Patient Engagement
Improve Patient Engagement
Patient Engagement promotes communication between the site and patient, which can make patients feel more involved in the overall process.
Simplify Participation
Simplify Participation
Virtually recreating the clinic experience, our Telemedicine reduces the number of in-person visits needed and offers flexibility to complete study assessments.
Digitalize the Entire Study
Digitalize the Entire Study
All the Signant SmartSignals solutions can be used as standalone tools or integrated with one another to further enhance the accuracy and efficiency of your IBD study.
